Videos
Round 1: Frontline Therapy for the Newly Diagnosed Patient
10/28/2026
The debate begins with a newly diagnosed patient with metastatic EGFR-mutated NSCLC. Panelists examine survival outcomes, durability of disease control, and mechanisms of acquired resistance, including implications for future treatment sequencing.
To see arguments related to frontline therapy for patients with CNS disease and other high-risk features, see Round 2.
To see arguments related to frontline therapy across age and fitness levels, see Round 3.
Transcript coming soon!
©️ 2026 HMP Global. All Rights Reserved.
This is a non-CME activity. The views and opinions expressed by the presenter(s) do not necessarily reflect the views and opinions of the Oncology Learning Network, HMP Global, or its employees and affiliates.
